Imipenem/Cilastatin/Relebactam (Recarbrio) for Carbapenem-Resistant Infections: First Triple-Combination Antibiotic (FDA Approved 2019)
Blujepa (Gepotidacin) for Uncomplicated UTIs: First-in-Class DNA Gyrase Inhibitor (FDA Approved June 2024)
Zaynich (Cefepime/Zidebactam) for Complicated UTIs: First-in-Class ?-Lactam/?-Lactamase Inhibitor IV Antibiotic (FDA Approved June 17, 2026) - Complete Treatment Guide vs Utebzi and Carbapenems 2026
Utebzi (Tebipenem Pivoxil) for Complicated UTIs: The First Oral Carbapenem Antibiotic (FDA Approved June 17, 2026) – Complete Treatment Guide
